ARTICLE | Clinical News
Agios discontinues development of AG-519 to treat pyruvate kinase deficiency
December 20, 2016 12:49 AM UTC
Agios said it discontinued development of AG-519 to treat pyruvate kinase deficiency after FDA placed a clinical hold on the candidate. On a conference call, the company said the hold was linked to a...
BCIQ Company Profiles
BCIQ Target Profiles